Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France
| dc.rights.license | open | en_US |
| dc.contributor.author | LAZZARO, Carlo | |
| dc.contributor.author | VAN STEEN, Cecile | |
| dc.contributor.author | APTEL, Florent | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | SCHWEITZER, Cedric | |
| dc.contributor.author | ANGELILLO, Luigi | |
| dc.date.accessioned | 2022-06-15T07:43:42Z | |
| dc.date.available | 2022-06-15T07:43:42Z | |
| dc.date.issued | 2022-04-29 | |
| dc.identifier.issn | 2090-004X (Print) 2090-004X (Linking) | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/140219 | |
| dc.description.abstractEn | PURPOSE: To investigate the cost utility of STN1013001, a latanoprost cationic emulsion, versus Latanoprost in patients with open-angle glaucoma or ocular hypertension (OAG/OHT) and concomitant ocular surface disease (OSD) in France. METHODS: An early Markov model, including 7 health states and a 1-year cycle length, was developed to estimate the cost utility of STN1013001 versus Latanoprost from the French health system perspective over a 5-year time horizon. The model was populated with pooled data (treatment adherence, quality of life, disease progression, and resource utilization) collected, via a questionnaire, from a convenience sample of 5 French glaucoma specialists. Remaining data were retrieved from published sources. Half-cycle correction and 2.5% real social discount rate were applied to costs (in €2020), life years saved (LYS), and quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was contrasted against the informal willingness-to-pay (WTP) range for incremental LYS or QALY gained (€30,000-€50,000) suggested for France. One-way and probabilistic sensitivity analyses tested the robustness of the baseline ICUR. RESULTS: Over a 5-year time horizon, STN1013001 resulted in an incremental 0.35 QALYs gained at an incremental cost of €7.39 compared to Latanoprost, resulting in an ICUR of €21.26. This is well below the lower limit of the unofficial WTP range proposed for France. Sensitivity analyses confirmed the robustness of the baseline results. CONCLUSION: Once on the market, STN1013001 will provide the French health system with a cost-effective treatment versus Latanoprost for OAG/OHT + OSD patients. These results should be confirmed by future economic evaluations carried out alongside empirical trials. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
| dc.title.en | Cost-Utility Analysis of STN1013001, a Latanoprost Cationic Emulsion, versus Other Latanoprost Formulations (Latanoprost) in Open-Angle Glaucoma or Ocular Hypertension and Ocular Surface Disease in France | |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1155/2022/3837471 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 35529166 | en_US |
| bordeaux.journal | Journal of Ophthalmology | en_US |
| bordeaux.volume | 2022 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | LEHA_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| bordeaux.identifier.funderID | Santen | en_US |
| bordeaux.identifier.funderID | AstraZeneca | en_US |
| bordeaux.identifier.funderID | Boehringer Ingelheim | en_US |
| bordeaux.identifier.funderID | CSL Behring | en_US |
| bordeaux.identifier.funderID | Ferring | en_US |
| bordeaux.identifier.funderID | Ipsen | en_US |
| bordeaux.identifier.funderID | Roche | en_US |
| bordeaux.identifier.funderID | Sanofi | en_US |
| bordeaux.identifier.funderID | Shire | en_US |
| hal.identifier | hal-03696620 | |
| hal.version | 1 | |
| hal.date.transferred | 2022-06-16T08:03:12Z | |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Ophthalmology&rft.date=2022-04-29&rft.volume=2022&rft.eissn=2090-004X%20(Print)%202090-004X%20(Linking)&rft.issn=2090-004X%20(Print)%202090-004X%20(Linking)&rft.au=LAZZARO,%20Carlo&VAN%20STEEN,%20Cecile&APTEL,%20Florent&SCHWEITZER,%20Cedric&ANGELILLO,%20Luigi&rft.genre=article |
